Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.8300 (4.61%) ($12.8300 - $12.8300) on Wed. Sep. 27, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.4% (three month average) | RSI | 58 | Latest Price | $12.8300(4.61%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.8% a day on average for past five trading days. | Weekly Trend | FOLD declines -2.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(71%) IBB(65%) ARKG(60%) CEMB(48%) IWO(48%) | Factors Impacting FOLD price | FOLD will decline at least -1.2% in a week (0% probabilities). TBT(-35%) UUP(-17%) VXX(-11%) URA(-3%) DRIV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.2% (StdDev 2.4%) | Hourly BBV | 1.6 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $6.6(-48.56%) | 5 Day Moving Average | $12.29(4.39%) | 10 Day Moving Average | $12.56(2.15%) | 20 Day Moving Average | $12.71(0.94%) | To recent high | -6.9% | To recent low | 9% | Market Cap | $3.313b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |